Subject
Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference10 articles.
1. US Food and Drug Administration. FDA workshop: clinical trial design for non-muscle invasive bladder cancer (NMIBC). November 18–19, 2021. https://www.fda.gov/drugs/news-events-human-drugs/fda-workshop-clinical-trial-design-non-muscle-invasive-bladder-cancer-nmibc-11182021.
2. International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Guérin–exposed high-risk non–muscle-invasive bladder cancer;Roumiguié;Eur Urol,2022
3. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial;Boorjian;Lancet Oncol,2021
5. IL-15 superagonist NAI in BCG-unresponsive non–muscle-invasive bladder cancer;Chamie;NEJM Evid,2022